Author: admin

Theft of signalling cables has caused “major disruption” on parts of the train network, National Rail said.

The cables were stolen at Napsbury, resulting in a fault with the signalling system at St Albans, Hertfordshire.

National Rail said East Midlands Railway services between Sheffield, Nottingham, Corby and London St Pancras were affected as well as Thameslink services between Bedford and East Croydon, and also between Luton and Rainham, in Kent.

A spokeswoman said work to replace the cables was taking place overnight and normal services were expected to resume at about 06:00 GMT on Sunday.

The company said the theft resulted in “major disruption” meaning that “trains running between Luton and London St Pancras International may be cancelled, severely delayed by up to 60 minutes or revised”.

On National Rail’s website, East Midlands Railway advised customers to expect delays as “trains are being manually sent through the affected area”.

Thameslink also told customers to expect lengthy delays and more frequent train change.

Alternative arrangements for travel have been posted on the National Rail site.

Story Continues

What counts as a “normal” P/E depends on what investors expect for future growth and how much risk they see in those earnings. Higher expected growth and lower perceived risk usually support a higher P/E, while lower growth or higher risk tend to mean a lower P/E.

Hitachi is currently trading on a P/E of 29.52x. That sits above the Industrials sector average of 12.98x and also above the peer group average of 13.32x. To add more context, Simply Wall St calculates a proprietary “Fair Ratio” for Hitachi of 36.10x, which reflects factors such as earnings growth, industry, profit margins, market cap and risk profile.

This Fair Ratio aims to be more tailored than a simple comparison with peers or the sector, because it adjusts for company specific traits rather than assuming all firms should trade on the same multiple. Compared with this Fair Ratio, Hitachi’s current P/E of 29.52x is lower, which points to the shares being undervalued on this measure.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1445 companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you turn your view of Hitachi into a clear story that links its business drivers to a forecast for revenue, earnings and margins, then to a Fair Value you can compare with the current price. All of this is updated as new news or earnings arrive. One investor might back a higher fair value around ¥5,300 if they think government backed energy and AI infrastructure and digital services can support stronger margins, while another might anchor closer to ¥3,900 if they are more cautious about competition, costs and underperforming segments.

Do you think there’s more to the story for Hitachi? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 6501.T.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months following treatment with an off-the-shefl chimeric antigen receptor (CAR) natural killer (NK) cell therapy alongside rituximab, according to leaders from ImmunityBio, who on Friday shared an update from an ongoing trial.¹

Durable CRs were seen in patients who had failed to response to current standard therapy. The treatment from ImmunityBio is the first chemotherapy-free, lymphodepletion-free CAR NK therapy to show 100% disease control in its first 4 patients, all of whom have been treated as outpatients, according to a statement from the company.¹

The update for the QUILT-106 clinical study (NCT06334991), which is ongoing, offered details for ImmunityBIo’s allogeneic cell therapy engineered to express a CD19-specific CAR NK and a high-affinity CD16 (FcγRIIIa 158V) receptor. The dual anti-tumor design creates a more potent tumor-fighting effect when paired with the anti-CD20 monoclonal antibody rituximab, as is the case in QUILT-106.¹

Rituximab targets CD20 on B cells,² and the QUILT-106 is using the combination regiment to treat Waldenström NHL, a rare B-cell malignancy whose patients have significant unmet need. Patients with Waldenström non-Hodgkins lymphoma who relapse or become refractory to available targeted and antibody-based therapies have limited options.¹

Patients received a total of 8 doses of cell therapy in the outpatient setting without lymphodepletion, which requires chemotherapy. Tumors were targeted with both CD19 and CD20 by infusing CD19 CAR NK cells with rituximab, 2 doses per cycle every 21 days for a total of 4 cycles (8 doses of NK-CAR and 6 doses of rituximab) and no further therapy thereafter. Responses were evaluated after 2 cycles.

The 2 patients in long-term follow-up remain in CR despite having no additional treatment, the company said in its statement.¹

Both the speed to remission and treatment’s durability show the potential for long-term immune-mediated disease control without continuous therapy, officials said, underscoring the current trend toward time-limited regimens that spare patients toxicity and achieve savings for health systems.³

“This updated follow-up reinforces the central thesis that restoring and activating the immune system can deliver durable control of disease without chemotherapy or lymphodepletion,” Patrick Soon‑Shiong, MD, ImmunityBio’s founder, executive chairman, and global chief medical and scientific officer said in a statement. “Seeing complete responses persist beyond a year after treatment has stopped, in patients who had exhausted available options, represents a meaningful advance for patients with this rare disease of Waldenström lymphoma and validates CAR-NK as a potential next-generation immunotherapy platform.”¹

In the 2 patients with evaluable follow up, 1 began with multiple lymphomatous bone lesions and 1 had with approximately 95% bone marrow infiltration by tumor cells. Both had complete responses after only 4 doses of CAR-NK plus rituximab.

Company officials said the patient with significant bone marrow involvement had complete bone morphological remission. In this patient, tumor cells had replaced 95% of the bone marrow, but after just 4 doses the patient achieved a CR that has now been maintained for 15 months, with no treatment beyond the scheduled 8 doses.

This approach “eliminates the need for cytotoxic conditioning for lymphodepletion or inpatient hospitalization, addressing key limitations associated with conventional CAR-T therapies,” ImmunityBio officials said in their statement.¹

“These data highlight a favorable safety and efficacy profile that is particularly important for patients with indolent yet incurable lymphomas,” Lennie Sender, MD, ImmunityBio chief medical officer for liquid tumors and cell therapy, said in the statement.¹So far, patients have not experienced any serious adverse events, Sender said.¹

ImmunityBio plans a follow-up study is that will combine the CAR-NK therapy, rituximab, and the company’s nogapendekin alfa inbakicept treatment, an immunotherapy marketed as Anktiva. This triplet will be evaluated in indolent lymphoma, including Waldenström’s macroglobulinemia.¹ At present, nogapendekin alfa inbakicept is approved by FDA with Bacillus Calmette-Guérin (BCG) to treat BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC), specifically with carcinoma in situ.⁴

References

1. ImmunityBio announces durable complete response of 15 months with a chemotherapy-free CD19 CAR-NK cell therapy in Waldenstrom lymphoma. News release. ImmunityBIo. January 16, 2026. Accessed January 17, 2026. https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-announces-durable-complete-response-15-months
2. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12(suppl 2:S1-4.
3. Caffrey M. Time-limited regimens gain notice, offering a break for patients with blood cancer and savings for payers. Am J Manag Care. 2026;32(Spec 1):SP12.
4. FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer. News release. April 22, 2024. Accessed January 17, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle-invasive-bladder-cancer